Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe
Clinical trial Global

Wegovy linked to greater AST and weight reductions in two real-world MASH analyses

Novo Nordisk announced on 6 November 2026 new real-world data from the retrospective PLATINUM-Truveta and RHODIUM-2 studies of Wegovy, its once weekly semaglutide injection, in adults with metabolic dysfunction-associated steatohepatitis (MASH), presented at the American Association for the Study of Liver Diseases, The Liver Meeting 2026, in Denver, Colorado.

Laboratory bench with blood sample tubes and a clinical analyser used for liver enzyme testing

What is Semaglutide?

Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk and sold as Ozempic (weekly injection, type 2 diabetes), Rybelsus (daily tablet, type 2 diabetes) and Wegovy (obesity, as a weekly injection and, since December 2025 in the US and July 2026 in the EU, as a daily pill).

Read the full guide →

In 30 seconds

  • In PLATINUM-Truveta, Wegovy, the once weekly semaglutide injection, was associated with a statistically significant mean weight loss from baseline of 18.9 lb (8.6 kg; about 8%) compared with resmetirom at six months, and with significantly greater reductions than resmetirom in AST.
  • In RHODIUM-2, adults with MASH who initiated the same once weekly injection had larger 12-month reductions in ALT, AST and body weight, plus a larger HbA1c decrease, than adults with MASH who did not initiate it.
  • Both studies were retrospective and observational, treatment was not randomized, and the release states that, as a general limitation of real-world data analyses, causal relationships cannot be definitively established.

Update: 8 November 2026

On 8 November 2026 Novo Nordisk announced results from a post hoc analysis of the phase 3 ESSENCE trial, presented in an oral presentation at The Liver Meeting 2026 in Denver, Colorado, covering a subgroup of 106 adults with MASH and liver scarring who had a BMI below 27 (out of the 800 randomised participants in the 72 week interim analysis of part 1). In that subgroup at week 72, the estimated effects of once weekly semaglutide injection (Wegovy) versus placebo favoured semaglutide for markers of liver injury (estimated treatment ratio 0.61 for ALT, 95% CI 0.48 to 0.79; 0.67 for AST, 95% CI 0.56 to 0.80), for disease activity (estimated treatment difference -0.13 for the FAST score, 95% CI -0.26 to -0.01) and for fibrosis markers (estimated treatment difference -0.45 for the ELF score, 95% CI -0.73 to -0.17; estimated treatment ratio 0.82 for PRO-C3, 95% CI 0.71 to 0.95), while the ratio for liver stiffness measured by elastography was 0.88 (95% CI 0.73 to 1.06), a confidence interval that included 1.0. Novo Nordisk states that these exploratory post hoc analyses are hypothesis generating and that further work investigating the clinical validity of the results would be of value; the findings supplement the histologic data reported in this subgroup for both primary endpoints, resolution of steatohepatitis without worsening of liver fibrosis and improvement in liver fibrosis without worsening of steatohepatitis. "This analysis is not about any single biomarker, but suggests a pattern across measures of liver injury, disease activity and fibrosis," said Professor Jörn Schattenberg, Director of the Department of Medicine II, Gastroenterology & Hepatology at the Saarland University Medical Center in Homburg and the University of the Saarland in Germany.

Why it matters

MASH is described in the release as a serious, progressive metabolic liver disease that can be fatal if not managed properly. More than 250 million people live with MASH, and nearly 90% of people with MASH remain undiagnosed. Of those currently living with MASH, more than 40% have type 2 diabetes and more than 8 in 10 also live with obesity, while cardiovascular disease is the leading cause of death in people with MASH.

Wegovy, the once weekly semaglutide injection studied in both analyses, is a glucagon-like peptide-1 receptor agonist that is FDA-approved under accelerated approval to treat adults with MASH with moderate-to-advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity. Both analyses report associations observed in routine clinical practice rather than results from a controlled trial: one compares the injection with resmetirom, the other compares adults who initiated it with adults who did not.

"Living with MASH can be incredibly challenging because the disease may progress without clear symptoms, making it even more important to understand the clinical data about how a treatment may help their disease," said Michelle Skinner Moore, PhD, MBA, Vice President, Medical Affairs at Novo. "The findings from PLATINUM-Truveta and RHODIUM offer insights into real-world results for patients treated for MASH and help to inform providers."

The details

  • PLATINUM-Truveta design: an observational, retrospective cohort study using de-identified electronic medical record data from the Truveta database across 30 US health systems from June 2021 through March 2026. It included 2,873 adults with MASH who initiated Wegovy, the once weekly semaglutide injection, and 2,285 adults with MASH who initiated resmetirom. Patients with prior use of semaglutide or resmetirom, cirrhosis or other chronic liver diseases were excluded, and treatment persistence was required at each time point.
  • PLATINUM-Truveta at three months (mean changes from baseline, Wegovy group versus resmetirom group): AST -6.7 versus -1.9 (p<0.001); ALT -8.7 versus -4.8 (p=0.077, not statistically significant); HbA1c -0.29 versus +0.03 percentage points (p<0.001); body weight -10.5 lb versus -1.5 lb (p<0.001); platelets +6.8 versus +2.7 (p=0.48).
  • PLATINUM-Truveta at six months: AST -10.4 versus -4.5 (p<0.001); ALT -14.8 versus -11.6 (p=0.20, not statistically significant); HbA1c -0.38 versus -0.08 percentage points (p<0.001); body weight -18.9 lb versus -5.6 lb (p<0.001); platelets +7.8 versus -4.4 (p=0.022). The headline figure of 18.9 lb (8.6 kg; about 8%) is the Wegovy group result at six months, against 5.6 lb in the resmetirom group.
  • How to read those numbers: the table describes the values as adjusted mean changes from baseline, and its footnote states that the values presented are weighted means without additional covariate adjustment. Negative values indicate reductions.
  • Where resmetirom did better: LDL fell more in the resmetirom group at both time points, -10.3 in the Wegovy group versus -20.7 with resmetirom at three months (p<0.05) and -13.7 versus -29.1 at six months (p<0.001). Triglycerides (-29.4 in the Wegovy group versus -30.5 with resmetirom, p=0.91) and HDL (+0.3 versus -1.4, p=0.29) at six months did not differ significantly.
  • RHODIUM-2 design: an observational, retrospective study on the same database, comparing 2,479 adults with MASH who initiated the once weekly semaglutide injection with 70,702 adults with MASH who did not initiate semaglutide. Patients with cirrhosis or other liver disease etiologies, and those treated with GLP-1 receptor agonists or resmetirom within six months before the start of first treatment, were excluded.
  • RHODIUM-2 at 12 months (adjusted mean changes, initiators versus no initiation): ALT -14.0 versus -3.8, adjusted between-group difference -10.5 (p<0.01); AST -9.1 versus -1.8, difference -7.3 (p=0.001); body weight -30.7 lb versus -2.4 lb, difference -28.4 (p<0.001). HbA1c was -0.46 versus -0.09 percentage points, from paired baseline and 12-month data, with the between-group difference and p value not reported.
  • Exploratory endpoints, elevated ALT subgroup (elevated ALT defined as ALT above 25 in women and above 35 in men): ALT -24.3 in initiators versus -10.7 with no initiation, difference -13.7 (p=0.002); AST -14.2 versus -5.3, difference -8.9 (p=0.002). The table labels these endpoints exploratory.
  • Clinician comment: "Every patient with MASH has different metabolic needs," said Dr. Eric Lawitz, Texas Liver Institute, and University of Texas Health San Antonio. "This real-world analysis offers insights that may help clinicians inform treatment decisions for people living with MASH."
  • Presentation status: PLATINUM-Truveta was selected as a Poster of Distinction, a designation given to the top 10% of submitted posters. Both analyses were presented as posters on Friday, November 6, within the 12 abstracts Novo flagged for the congress, which ran November 5 to 9.
  • Safety labelling: the release notes that the Wegovy injection has a Boxed Warning for possible thyroid tumors, including cancer, and should not be used in those with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). The most common side effects listed include nausea, diarrhea, vomiting, constipation and stomach pain.

What it does not change

These are not trial results and not a regulatory event. Both studies were retrospective and observational: treatment was not randomized, the groups differed in baseline characteristics, and results were based on patients with available follow-up measurements who met treatment-persistence criteria. The release states, as a general limitation of real-world data analyses, that while associations can be demonstrated, causal relationships cannot be definitively established. The approval status of the injection is unchanged: accelerated approval is based on improvement of MASH and liver scarring (fibrosis), and continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. The data also say nothing about people with cirrhosis, who were excluded from both analyses and are outside the approved population.

What's next

Novo is investigating the same once weekly subcutaneous injection in the ongoing ESSENCE phase 3 trial in adults with MASH with moderate-to-advanced liver scarring (fibrosis), consistent with stage F2 or F3. ESSENCE randomized 1,197 participants 2:1 to Wegovy or placebo on top of standard of care for 240 weeks. In part 1, the objective was to demonstrate improvement in liver histology at 72 weeks compared with placebo, based on biopsy sampling from the first 800 randomized patients. In part 2, which is ongoing, the primary objective is to demonstrate that treatment lowers the risk of liver-related clinical events compared to placebo at 240 weeks. Also at the congress, Novo listed clinical trial data from a post hoc analysis of ESSENCE in people with a BMI below 27, presented as an oral presentation on Sunday, November 8, and four posters including one oral presentation on investigational efruxifermin, with new analyses from the phase 2b SYMMETRY trial in compensated MASH cirrhosis.

What we don't know yet

Several gaps remain. The RHODIUM-2 HbA1c comparison has no reported between-group difference or p value, so the size of that gap is not quantified in the release. In PLATINUM-Truveta, the ALT difference between the two groups was not statistically significant at either time point, so that study does not establish an ALT benefit over resmetirom. The elevated ALT findings are exploratory, and the announcement states that exploratory post hoc analyses are hypothesis generating and that further work investigating the clinical validity of these results would be of value. Results may reflect potential unmeasured confounding, the relatively recent approval of both treatments limited follow-up duration, and electronic medical record data may be subject to coding inaccuracies. No liver histology or clinical event outcomes are reported in either real-world analysis, and the accepted abstracts include preliminary data that may be subject to change in the final published manuscripts.

Products sold online as research peptides are not the medicines studied or approved in this news. A medicine is available in a country only after that country's medicines agency approves it.

Source documents

This article reports news for information only. It is not medical or legal advice and does not recommend any use or dose. Every fact comes from the source documents listed above.